

In re Patent Application of

ARMOUR et al.

Atty. Ref.:

620-117

Serial No. 09/674,857

Group:

1644

Filed: November 7, 2000

Examiner:

Huynh, P.

For: BINDING MOLECULES DERIVED FROM

IMMUNOGLOBULINS WHICH DO NOT TRIGGER

COMPLEMENT MEDIATED LYSIS

DEC 2 7 2002

TECH CENTER 1600/2900

November 7, 2002

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

Sir:

SECOND REQUEST FOR CORRECTION OF FILING RECEIPT

Enclosed is a copy of a Corrected Filing Receipt for the above-identified application which makes reference to an incorrect foreign application number. Under the heading "Foreign Applications", please change "UNITED KINGDOM 0909951.8 05/08/1998" to --UNITED KINGDOM 9809951.8 05/08/1998--. The correction is shown in red on the attached copy of the filing receipt. Please note your records accordingly. Correction of same is respectfully requested.

ARMOUR et al. Serial No. 09/674,857

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 17 ((

Mary J. Wilson Reg. No. 32,955

MJW:tat

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100





COMMISSIONER FOR PATEN UNITED STATES PATENT AND TRADEMARK OFFIC WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER
09/674.857

FILING DATE 11/07/2000

GRP ART UNIT

1058

ATTY.DOCKET.NO 620-117

DRAWINGS

TOT CLAIMS

IND CLAIMS

Nixon & Vanderhye 8th Floor 1100 North Glebe Road Arlington, VA 22201-4714 CONFIRMATION NO. 5675
CORRECTED FILING RECEIPT
CO000000006537902*

Date Mailed: 09/10/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kathryn Armour, Cambridge, GBN; Michael Ronald Clark, Cambridge, GBN; Lorna McLeod Williamson, Cambridge, GBN;

RECEIVED

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/GB99/01441 05/07/1999

DEC 2 7 2002 TECH CENTER 1600/2900

Foreign Applications

9809951.8

UNITED KINGDOM 0909951,8 05/08/1998

If Required, Foreign Filing License Granted 02/09/2001

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

Title

Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis

Preliminary Class

Data entry by : JONES, KIMBERLY

Team: 2800

Date: 09/10/2001



GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231